Physician profile
Deepa Abraham
NPI 1760927172
$4,712.72
in general payments reported to CMS, 2019-2025
36 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $935 · 2022: $1,176 · 2023: $87.56 · 2024: $549 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.81 |
| Education | $106.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $639.57 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $627.83 | 2025 | Dupixent |
| Lilly USA, LLC | $537.60 | 2021-2025 | Ebglyss, Mounjaro, Zepbound |
| Amgen INC. | $504.18 | 2021-2025 | Tezspire, Otezla, Repatha |
| Novo Nordisk INC | $371.34 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $241.77 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $183.62 | 2022 | |
| Abbvie INC. | $170.28 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.14 | 2025 | Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $147.19 | 2025 | |
| Amarin Pharma, INC. | $129.25 | 2021-2022 | |
| Genzyme Corporation | $121.84 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.53 | 2022-2024 | |
| Azurity Pharmaceuticals, INC. | $82.22 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $79.39 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $73.55 | 2021-2022 | |
| Redhill Biopharma INC. | $54.29 | 2021 | |
| Exact Sciences Corporation | $52.89 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $35.62 | 2021 | |
| Philips North America LLC | $35.53 | 2024 | (Ck7) Extended Holter |
| Alk-Abello, INC | $29.67 | 2025 | Timothy, Standardized, Standardized Mite D. Farinae, Histamine Positive |
| Medtronic, INC. | $28.25 | 2022 | |
| Si-Bone, INC. | $27.86 | 2021 | |
| Boston Scientific Corporation | $27.37 | 2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $25.66 | 2021-2024 | |
| Incyte Corporation | $25.48 | 2025 | Opzelura |
| Csl Behring | $24.46 | 2025 | Hizentra, Privigen |
| Kedrion Biopharma, INC. | $24.24 | 2025 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Octapharma USA, INC. | $24.24 | 2025 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $23.34 | 2025 | Neffy |
| Shield Therapeutics INC | $22.80 | 2022 | |
| Arcutis Biotherapeutics, INC. | $21.10 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $17.62 | 2021 | |
| Pfizer INC. | $16.38 | 2022 | |
| Eisai INC. | $16.21 | 2021 | |
| Cequr Corporation | $10.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.